Mayne Pharma
Claire Hying has a diverse work experience spanning over two decades. Claire currently holds the position of Director, Financial Planning & Analysis at Mayne Pharma since July 2022. Prior to this, they worked as an Associate Director, Financial Planning & Analysis at Mayne Pharma, as well as a Senior Manager, US Financial Planning & Analysis and Manager, Corporate Financial Planning & Analysis, both at Mayne Pharma.
Before their time at Mayne Pharma, Claire worked at Allscripts as an Associate Manager Finance, Senior Financial Analyst, and Financial Analyst. Prior to Allscripts, they participated in a 20-month finance leadership program, the Finance Enterprise Associate program, at Wachovia, A Wells Fargo Company.
Claire also has experience in the banking and real estate industry, having worked as a Teller at First Citizens Bank and as a Receptionist at Re/MAx Preferred Associates. Claire began their career as a Junior Sales Assistant at Smith Barney.
Claire Hying completed their education at Sanderson High School from 1999 to 2003. Claire then pursued a degree in Business Management at the North Carolina State University - College of Management from 2003 to 2007. Later, Claire obtained a Master of Business Administration (MBA) with a focus on Finance, General from North Carolina State University, which they achieved from 2012 to 2015.
This person is not in any offices
Mayne Pharma
1 followers
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.